{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:03:12Z","timestamp":1792152192875,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004590","name":"Helse Midt-Norge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004590","id-type":"DOI","asserted-by":"publisher"}]},{"name":"St.Olavs Hospital, Trondheim University Hospital"},{"DOI":"10.13039\/100009123","name":"Norwegian University of Science and Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009123","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-vascular endothelial growth factor is a medicine administered intravitreally by an injection to maintain visual acuity in patients with a variety of retinal diseases. The demand for this treatment has grown considerably in the westernized world the last two decades and will continue to increase due to an aging population. Because of the high volume, injections seize enormous resources and represent high costs for both hospitals and society. Task-shifting of injections from physicians to nurses may be a means to reduce such costs, however the magnitude of possible savings has been poorly investigated. To this end we investigated changes in the hospital costs per injection, six-year cost projections of physician- versus nurse-administered injections for a Norwegian tertiary hospital and we compared the societal costs per patient per year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients (<jats:italic>n<\/jats:italic>\u2009=\u2009318) were randomized to either physician- or nurse administered injections, and data were prospectively collected. Hospital costs per injection were calculated as the sum of training costs, personnel time and running expenses. The number of injections for the years 2014 \u2013 21 from a Norwegian tertiary hospital was combined with age group specific injection prevalence and population projections to calculate cost projections for 2022 \u2013 27. Societal costs per patient were calculated as the sum of hospital costs, transport costs for patients, caregivers\u2019 use of time, costs of ophthalmology consultations and community-based homecare.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The hospital costs per injection were 5.5 \u20ac higher for physicians compared to nurses (281.6 \u20ac versus 276.1 \u20ac). Cost projections estimated an annual hospital saving of task-shifting of 48\u00a0921 \u20ac for 2022 \u2013 27. Societal costs per patient did not differ significantly between the two groups (mean 4988 \u20ac vs 5418 \u20ac, <jats:italic>p<\/jats:italic>\u2009=\u20090.398).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Task-shifting of injections from physicians to nurses can reduce hospital costs and increase the flexibility of physician resources. The annual savings are modest, but increased demand for injections might increase future cost savings. To achieve future savings for society, organizing ophthalmology consultations and injections on the same day to reduce the number of visits might be a solution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT02359149 (09\/02\/2015).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-09186-0","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T17:04:30Z","timestamp":1678295070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norway"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-9545","authenticated-orcid":false,"given":"Stine","family":"Bolme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dordi","family":"Austeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tora Sund","family":"Morken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid","family":"Follestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidar","family":"Halsteinli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"4","key":"9186_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 Update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181\u201393.","journal-title":"Ophthalmologica"},{"issue":"9","key":"9186_CR2","first-page":"1260","volume":"27","author":"A Almony","year":"2021","unstructured":"Almony A, Keyloun KR, Shah-Manek B, Multani JK, McGuiness CB, Chen CC, et al. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. J Manag Care Spec Pharm. 2021;27(9):1260\u201372.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"9186_CR3","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s10792-021-01906-x","volume":"41","author":"JM Ruiz-Moreno","year":"2021","unstructured":"Ruiz-Moreno JM, Arias L, Abraldes MJ, Montero J, Udaondo P. Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. Int Ophthalmol. 2021;41(10):3427\u201336.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"9186_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/aos.14184","volume":"98","author":"S Bolme","year":"2020","unstructured":"Bolme S, Morken TS, Follestad T, S\u00f8rensen TL, Austeng D. Task shifting of intraocular injections from physicians to nurses: a randomized single-masked noninferiority study. Acta Ophthalmol (Copenh). 2020;98(2):139\u201344.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"9186_CR5","unstructured":"Statistics Norway. Inflation calculator: Statistics Norway. 2022. Available from: https:\/\/www.ssb.no\/en\/kalkulatorer\/priskalkulator. Accesses 28 Feb 2023."},{"key":"9186_CR6","unstructured":"Statistics Norway. Official statistics since 1876: Statistics Norway. 2022. Available from: https:\/\/www.ssb.no\/en. Accessed 28 Feb 2023."},{"key":"9186_CR7","unstructured":"Gule Sider AS. Gulesider web based map. Gule Sider AS. 2022. Available from: https:\/\/kart.gulesider.no\/veibeskrivelse. Accessed 28 Feb 2023."},{"key":"9186_CR8","doi-asserted-by":"publisher","unstructured":"Austeng D, Morken TS, Bolme S, Follestad T, Halsteinli V. Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. BMC Ophthalmol. 2016;16(1):169. https:\/\/doi.org\/10.1186\/s12886-016-0348-4.","DOI":"10.1186\/s12886-016-0348-4"},{"key":"9186_CR9","unstructured":"Helse Norge. Norwegian health care services user fee and rates for patient travels. HelseSatser for dekning av pasientreiser Oslo: Helse Norge. 2021. Available from: https:\/\/www.helsenorge.no\/pasientreiser\/rettigheter\/egenandel-og-satser\/#satser-for-2021. Accessed 24 Feb 2022."},{"key":"9186_CR10","unstructured":"AtB in Trondelag. Singel ticket fares Trondheim: AtB; 2022. Available from: https:\/\/www.atb.no\/en\/single-ticket\/. Accessed 24 Feb 2022."},{"issue":"11","key":"9186_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/s41433-020-0920-2","volume":"34","author":"AWJ Teo","year":"2020","unstructured":"Teo AWJ, Rim TH, Wong CW, Tsai ASH, Loh N, Jayabaskar T, et al. Design, implementation, and evaluation of a nurse-led intravitreal injection programme for retinal diseases in Singapore. Eye (Lond). 2020;34(11):2123\u201330.","journal-title":"Eye (Lond)"},{"issue":"8","key":"9186_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.oret.2017.12.006","volume":"2","author":"S Patel","year":"2018","unstructured":"Patel S. Medicare spending on anti-vascular endothelial growth factor medications. Ophthalmol Retina. 2018;2(8):785\u201391.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"9186_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","volume":"138","author":"K Mulligan","year":"2020","unstructured":"Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol. 2020;138(1):40\u20137.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"9186_CR14","doi-asserted-by":"publisher","first-page":"e055478","DOI":"10.1136\/bmjopen-2021-055478","volume":"12","author":"JV Rocha","year":"2022","unstructured":"Rocha JV, Marques AP, Macedo AF, Afonso-Silva M, Laires P, Almeida AS, et al. Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013\u20132018): a retrospective analysis of administrative data. BMJ Open. 2022;12(4):e055478.","journal-title":"BMJ Open"},{"key":"9186_CR15","unstructured":"World Health Organization. Task shifting: global recommendations and guidelines: World Health Organization; 2008. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43821\/9789?sequence=1#:~:text=The%20recommendation%20endorses%20task%20shifting,in%20human%20resources%20for%20health."},{"issue":"7","key":"9186_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/aos.12781","volume":"93","author":"A Rasmussen","year":"2015","unstructured":"Rasmussen A, Brandi S, Fuchs J, Hansen LH, Lund-Andersen H, Sander B, et al. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol. 2015;93(7):616\u201320.","journal-title":"Acta Ophthalmol"},{"key":"9186_CR17","unstructured":"The Norwegian academy of Ophthalmology. KONUS rapport. Alexander Skau: The Norwegian academy of Ophthalmology;\u00a02012.\u00a0http:\/\/legeforeningen.no\/Fagmed\/Norsk-oftalmologisk-forening\/Nyheter\/2012\/KONUS-rapporten-er-na-publisert\/.\u00a0"},{"key":"9186_CR18","doi-asserted-by":"publisher","unstructured":"Bolme S, Austeng D, Gjeilo KH. Task shifting of intravitreal injections from physicians to nurses: a qualitative study. BMC Health Serv Res. 2021;21(1):1185.\u00a0https:\/\/doi.org\/10.1186\/s12913-021-07203-8.","DOI":"10.1186\/s12913-021-07203-8"},{"issue":"6","key":"9186_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/eye.2014.69","volume":"28","author":"J DaCosta","year":"2014","unstructured":"DaCosta J, Hamilton R, Nago J, Mapani A, Kennedy E, Luckett T, et al. Implementation of a nurse-delivered intravitreal injection service. Eye (Lond). 2014;28(6):734\u201340.","journal-title":"Eye (Lond)"},{"key":"9186_CR20","doi-asserted-by":"publisher","unstructured":"Simcock P, Kingett B, Mann N, Reddy V, Park J. A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners. Eye (Lond). 2014;28(10):1161\u20134.\u00a0https:\/\/doi.org\/10.1038\/eye.2014.153.","DOI":"10.1038\/eye.2014.153"},{"issue":"1438","key":"9186_CR21","first-page":"32","volume":"129","author":"P Samalia","year":"2016","unstructured":"Samalia P, Garland D, Squirrell D. Nurse specialists for the administration of anti-vascular endothelial growth factor intravitreal injections. N Z Med J. 2016;129(1438):32\u20138.","journal-title":"N Z Med J"},{"issue":"6","key":"9186_CR22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41433-017-0008-9","volume":"32","author":"R Mohamed","year":"2018","unstructured":"Mohamed R, Ramcharan D, Srikaran S, Mensch E. A model of clinical practice: a randomised clinical study evaluating patient satisfaction of nurse-led vs consultant-led intravitreal injection. Eye (Lond). 2018;32(6):1148\u20139.","journal-title":"Eye (Lond)"},{"issue":"2","key":"9186_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","volume":"127","author":"DS Liao","year":"2020","unstructured":"Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186\u201395.","journal-title":"Ophthalmology"},{"issue":"4","key":"9186_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Westby K, Csaky KG, Mon\u00e9s J, Pearlman JA, Patel SS, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial. Ophthalmology. 2021;128(4):576\u201386.","journal-title":"Ophthalmology"},{"issue":"6","key":"9186_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3928\/23258160-20210528-05","volume":"52","author":"DS Boyer","year":"2021","unstructured":"Boyer DS, Gonzalez VH, Kunimoto DY, Maturi RK, Roe RH, Singer MA, et al. Safety and efficacy of intravitreal risuteganib for non-exudative AMD: a multicenter, phase 2a, randomized, clinical trial. Ophthalmic Surg Lasers Imaging Retina. 2021;52(6):327\u201335.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"April 2020","key":"9186_CR26","first-page":"38","volume":"17","author":"M Singer","year":"2020","unstructured":"Singer M, Rahman EZ. Update on longer-acting anti-VEGF therapies an expansive horizon is coming into focus. Retinal Physician. 2020;17(April 2020):38\u201341.","journal-title":"Retinal Physician"},{"key":"9186_CR27","first-page":"1","volume":"36","author":"R Chopra","year":"2021","unstructured":"Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye (Lond). 2021;36:1\u20136.","journal-title":"Eye (Lond)"},{"issue":"2","key":"9186_CR28","first-page":"147","volume":"49","author":"KD Bertakis","year":"2000","unstructured":"Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. J Fam Pract. 2000;49(2):147\u201352.","journal-title":"J Fam Pract"},{"issue":"3","key":"9186_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0164027501233003","volume":"23","author":"M Glasser","year":"2001","unstructured":"Glasser M, Prohaska T, Gravdal J. Elderly patients and their accompanying caregivers on medical visits. Res Aging. 2001;23(3):326\u201348.","journal-title":"Res Aging"},{"issue":"3","key":"9186_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/aos.14262","volume":"98","author":"IS Kristiansen","year":"2020","unstructured":"Kristiansen IS, Haugli Br\u00e5ten R, J\u00f8rstad \u00d8K, Moe MC, Saether EM. Intravitreal therapy for retinal diseases in Norway 2011\u20132015. Acta Ophthalmol. 2020;98(3):279\u201385.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"9186_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89\u201399.","journal-title":"Ophthalmology"},{"issue":"8","key":"9186_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","volume":"5","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Callanan D, Dreyer R, Chen S, Howard JG, Hopkins JJ, et al. End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2021;5(8):775\u201387.","journal-title":"Ophthalmol Retina"},{"key":"9186_CR33","unstructured":"World Medical Association. Declaration of Helsinki The World Medical Association; 2008. Available from: https:\/\/www.wma.net\/what-we-do\/medical-ethics\/declaration-of-helsinki\/doh-oct2008\/. Accessed 30 Mar\u00a02022."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09186-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T17:07:53Z","timestamp":1678295273000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9186"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09186-0","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"9 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is based on a RCT that followed the declaration of Helsinki [] and was approved by the Regional Committee for Medical and Health Research Ethics, South-Eastern Norway (2014\/1719). The study protocol was registered at ClinicalTrials.gov (NCT02359149) 09\/02\/2015. The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations. Participants were informed about the study by a project staff member and received a written information letter. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}